Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet.
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
Overview
Deciding between a pharmaceutical giant and a niche medical innovator depends on your risk tolerance. Amgen (NASDAQ:AMGN) and NovoCure (NASDAQ:NVCR) offer vastly different paths to potential growth in 2026.
Amgen is a global leader in drug manufacturing, focusing on large-scale treatments for chronic conditions. NovoCure specializes in proprietary wearable technology to treat various forms of cancer. Comparing them highlights the trade-off between the steady earnings of established healthcare giants and the high-stakes potential of specialized medical technology developers.
Details
Amgen develops and sells innovative medicines for heart disease, obesity, and cancer. Its revenue is highly concentrated among three pharmaceutical wholesalers: McKesson (NYSE:MCK), Cencora (NYSE:COR), and Cardinal Health (NYSE:CAH). Customer concentration like this adds a layer of risk to the business.
Source
Originally published at www.fool.com.
